Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease

[1]  Rudi D'Hooge,et al.  Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice* , 2005, Journal of Biological Chemistry.

[2]  T. Meert,et al.  Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides , 2005, Journal of Neuroscience Methods.

[3]  G. Binetti,et al.  BACE-2 is overexpressed in Down’s syndrome , 2003, Experimental Neurology.

[4]  B. Hyman,et al.  Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.

[5]  Bruce J Aronow,et al.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Becker,et al.  Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome , 2002, Neuroscience Letters.

[7]  C. Masters,et al.  Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease , 2002 .

[8]  R. Doms,et al.  β-Secretase Processing in the Trans-Golgi Network Preferentially Generates Truncated Amyloid Species That Accumulate in Alzheimer's Disease Brain* , 2002, The Journal of Biological Chemistry.

[9]  J. Kornhuber,et al.  Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.

[10]  R. Doms,et al.  Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. , 2002, Biochemistry.

[11]  D. Selkoe,et al.  Intraneuronal Aβ42 accumulation in Down syndrome brain , 2002 .

[12]  D. Selkoe,et al.  Intraneuronal Abeta42 accumulation in Down syndrome brain. , 2002, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[13]  C. Masters,et al.  Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. , 2002, Annals of neurology.

[14]  R. Doms,et al.  Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. , 2002, The Journal of biological chemistry.

[15]  E. Rüther,et al.  Elevation of β-Amyloid Peptide 2–42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells* , 2001, The Journal of Biological Chemistry.

[16]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[17]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.

[18]  B. de Strooper,et al.  Processing of β-Secretase by Furin and Other Members of the Proprotein Convertase Family* , 2001, The Journal of Biological Chemistry.

[19]  V. Dolcini,et al.  Identification of Amino-Terminally and Phosphotyrosine-Modified Carboxy-Terminal Fragments of the Amyloid Precursor Protein in Alzheimer's Disease and Down's Syndrome Brain , 2001, Neurobiology of Disease.

[20]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[21]  S. Younkin,et al.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  H. Cai,et al.  BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. , 2001, Nature neuroscience.

[23]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. , 2001, Nature neuroscience.

[24]  T. L. Tekirian.  Commentary: Abeta N- Terminal Isoforms: Critical contributors in the course of AD pathophysiology. , 2001, Journal of Alzheimer's disease : JAD.

[25]  V. Dolcini,et al.  Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. , 2001, Neurobiology of disease.

[26]  C. Schnitzler,et al.  BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein , 2000 .

[27]  M. Citron,et al.  Expression Analysis of BACE2 in Brain and Peripheral Tissues* , 2000, The Journal of Biological Chemistry.

[28]  F. Acquati,et al.  The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region , 2000, FEBS letters.

[29]  C. Southan,et al.  ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. , 2000, Molecular and cellular neurosciences.

[30]  C. Schnitzler,et al.  BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[32]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[33]  J. Trojanowski,et al.  Quantification of Modified Amyloid β Peptides in Alzheimer Disease and Down Syndrome Brains , 1998, Journal of neuropathology and experimental neurology.

[34]  Y. Sakaki,et al.  Presenilin 1 Mutations Linked to Familial Alzheimer's Disease Increase the Intracellular Levels of Amyloid β‐Protein 1–42 and Its N‐Terminally Truncated Variant(s) Which Are Generated at Distinct Sites , 1998, Journal of neurochemistry.

[35]  M. Raskind,et al.  Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis , 1998, Experimental Neurology.

[36]  M. Emmerling,et al.  Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. , 1997, Biochemical and biophysical research communications.

[37]  J. Trojanowski,et al.  Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. , 1996, The American journal of pathology.

[38]  D. Selkoe,et al.  Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation , 1996, Neurobiology of Disease.

[39]  D. Mann,et al.  Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome , 1996, Nature Medicine.

[40]  Carl W. Cotman,et al.  Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro(*) , 1995, The Journal of Biological Chemistry.

[41]  D. Mann,et al.  Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome , 1995, Annals of neurology.

[42]  D. Mann,et al.  Dominant and differential deposition of distinct β-amyloid peptide species, Aβ N3(pE), in senile plaques , 1995, Neuron.

[43]  D. Mann,et al.  Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. , 1995, Neuron.

[44]  C. Cotman,et al.  Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. , 1995, The Journal of biological chemistry.

[45]  P. Greengard,et al.  Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.